Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Narayanan to lead SeQuent through next phase of consolidation and growth
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Subscribe To Our Newsletter & Stay Updated
